VivoSeq
Other

Stage IV NSCLC

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Stage IV NSCLC is an early-stage landscape with 0 programs across 1 company. The most active players are Acrotech Biopharma Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Acrotech Biopharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Unknown status4 · 33%
Completed4 · 33%
Active, not recruiting1 · 8%
Recruiting1 · 8%
Withdrawn1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Recruiting·FFox Chase Cancer Center·Phase 2·NCT03786692·117 enrolled
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
Active, not recruiting·NNational Taiwan University Hospital·Phase 2·NCT05215548·100 enrolled
Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Completed·—·Phase 2·NCT02658097·13 enrolled
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Completed·AAcrotech Biopharma Inc.·Phase 1/2·NCT01310244·23 enrolled
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Completed·SSichuan University·Phase 1·NCT03812549·29 enrolled
AUY922 in Patient With Stage IV NSCLC
Completed·NNational Taiwan University Hospital·Phase 2·NCT01922583·31 enrolled
Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC
Terminated·NNYU Langone Health·Phase 2·NCT05691829·19 enrolled
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
Withdrawn·WWuhan University·Phase 2·NCT02623595
SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
Unknown status·—·N/A·NCT05583409·72 enrolled
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
Unknown status·GGuizhou Medical University·Phase 2·NCT03987087·68 enrolled
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT02976740·48 enrolled
Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC
Unknown status·SShanghai Chest Hospital·Phase 2·NCT02669719·70 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)